Click image to view it in full size

Frost & Sullivan provides outlook for the global pharmaceuticals market for 2022 and beyond, including emerging trends, growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting global mitigation of the pandemic, with severe implications on the health, social and economic well-being of people globally and delaying endemicity. Spurred by the ongoing pandemic situation, pharma and biotech has accelerated its pace of transformation, and the concept of clinical trial decentralization, data-driven R&D, digitalization of supply-chain and outsourcing has taken center stage.

The new vision in 2022 is focused on supply-chain resilience and adoption of innovative technologies to improve efficiency while ensuring healthcare remains precise, preventive, and outcome-based in the promotion of social and financial inclusion. With focus on COVID-19 on in terms of drug research and therapy administration in 2021, this trend is expected to change in end of 2022, with oncology and CNS expected to be the leading growth areas for the market. Value based care is taking center stage leading to shift towards platform and data based drug discovery and development models.